Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab Prices Share Offering for Hong Kong, New York

04/21/2021 | 06:35am EDT


© MT Newswires 2021
All news about ZAI LAB LIMITED
10/21ZAI LAB : Phase Ib Study of Psoriasis Treatment in Australia Yields Positive Topline Resul..
MT
10/21ZAI LAB : Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-..
BU
10/21Crescendo Biologics Announces Zai Lab Achieves Proof-of-Concept for ZL-1102 (Humabody, ..
CI
10/20ZAI LAB : ZL-1102, Zai Lab's Internally Developed Novel Human VH Antibody Fragment, Achiev..
PU
10/20ZL-1102, Zai Lab?s Internally Developed Novel Human VH Antibody Fragment, Achieved Proo..
CI
10/20ZAI LAB : ZL-1102, Zai Lab's Internally Developed Novel Human VH Antibody Fragment, Achiev..
GL
10/20ZL-1102, Zai Lab's Internally Developed Novel Human VH Antibody Fragment, Achieved Proo..
GL
10/20Zai Lab Limited Announces Positive Results from a Randomized and Efficacy of a Topical ..
CI
10/20Zai Lab Announces Topline Results from the Attack Trial
CI
10/19ZAI LAB : Entasis Say Sulbactam-Durlobactam Met Primary Endpoint in Phase 3 Trial in Acine..
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2021 155 M - -
Net income 2021 -511 M - -
Net cash 2021 1 481 M - -
P/E ratio 2021 -15,5x
Yield 2021 -
Capitalization 9 612 M 9 612 M -
EV / Sales 2021 52,5x
EV / Sales 2022 25,8x
Nbr of Employees 1 194
Free-Float 100,0%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 100,75 $
Average target price 212,07 $
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Tao Fu President, Chief Operating Officer & Director
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-25.56%9 612
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464